Nutraceuticals for the treatment of metabolic diseases: evidence from clinical practice

References

• Zeisel SH. Regulation of “nutraceuticals.”. Science 1999;285:1853-5
   PubMed Web of Science ®Google Scholar
• Biesalski HK. Nutraceuticals: the link between nutrition and medicine. In: Kramer K, Hoppe PP, Packer L, editors. Nutraceuticals in health and disease prevention. Marcel Dekker Inc.; New York. 2001;1-26
   Google Scholar
• Whitman M. Understanding the perceived need for complementary and alternative nutraceuticals: lifestyle issues. Clin J Oncol Nurs 2001;5:190-4
   PubMedGoogle Scholar
• Stauffer JE. Nutraceuticals. Cereal Foods World 1999;44:115-17
   Web of Science ®Google Scholar
• Cicero AFG, Derosa G, Bove M, et al. A nutraceutical based approach to reduce cholesterolaemia in patients previously intolerant of more than a statin: a pilot study. Mediterr J Nutr Metab 2008;1:33-6
   Google Scholar
• Cicero AFG, Derosa G, Bove M, et al. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Top Nutraceut R 2009;7(3/4):121-6
   Web of Science ®Google Scholar
• Cicero AF, Derosa G, Di Gregori V, et al. Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens 2010;32(2):137-44
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, Fogari E, et al. Effects of n-3 PUFAs on insulin resistance after an oral fat load. Eur J Lipid Sci Technol 2011;113(8):950-60
   Web of Science ®Google Scholar
• Derosa G, Cicero AFG, Fogari E, et al. n-3 PUFAs effects on post-prandial variation of metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol 2012;6(6):553-64
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Derosa G, Bove M, et al. Psyllium improves dyslipidaemia, hyperglycaemia and hypertension, while guar gum reduces body weight more rapidly in patients affected by metabolic syndrome following an AHA Step 2 diet. Mediterr J Nutr Metab 2010;3:47-54
   Google Scholar
• Cicero AF, Derosa G, Miconi A, et al. Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? Biofactors 2005;23(1):7-14
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, et al. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010;57(9):777-86
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Ferrari I, et al. Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol 2011;25(5):642-51
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010;49(16):1717-25
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2011;60(3):421-9
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AFG, Gaddi A, et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25(5):1429-39
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Derosa G. Rice bran and its main components: potential role in the management of coronary risk factors. Curr Top Nutraceut R 2005;3(1):29-46
   Google Scholar
• Cicero AF, Derosa G, Borghi C. Red yeast rice and statin-intolerant patients. Am J Cardiol 2010;105(10):1504
   PubMed Web of Science ®Google Scholar
• Caron MF, White CM. Evaluation of the antihyperlipidemic properties of dietary supplements. Pharmacotherapy 2001;21(4):481-7
   PubMed Web of Science ®Google Scholar
• Ferrari CK. Functional foods, herbs and nutraceuticals: towards biochemical mechanisms of healthy aging. Biogerontology 2004;5(5):275-89
   PubMed Web of Science ®Google Scholar
• Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286-91
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1-12
   PubMedGoogle Scholar
• Rajasekar P, Anuradha CV. Effect of L-carnitine on skeletal muscle lipids and oxidative stress in rats fed high-fructose diet. Exp Diabetes Res 2007;2007:72741
   PubMedGoogle Scholar
• Malaguarnera M, Gargante MP, Russo C, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial. Am J Gastroenterol 2010;105(6):1338-45
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, Sowers JR. Hypertension and insulin resistance. Hypertension 2009;54(3):462-4
   PubMed Web of Science ®Google Scholar
• Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57(5):712-17
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei J, Xue R, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 2010;59(2):285-92
   PubMed Web of Science ®Google Scholar
• Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012;4(3):77-83
   PubMedGoogle Scholar
• Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab 2008;93(7):2559-65
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12(8):1113-24
   PubMed Web of Science ®Google Scholar
• Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS Pharm Sci Tech 2011;12(2):705-11
   PubMed Web of Science ®Google Scholar
• Pan GY, Wang GJ, Liu XD, et al. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 2002;91(4):193-7
   PubMedGoogle Scholar
• Chae HW, Kim IW, Jin HE, et al. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch Pharm Res 2008;31(1):103-10
   PubMed Web of Science ®Google Scholar
• Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998;3(6):410-21
   PubMedGoogle Scholar
• Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36(1):57-104
   PubMed Web of Science ®Google Scholar
• Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005;10(3):193-203
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 2013;13(11):1495-506
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Bonaventura A, et al. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther 2013;13(4):475-82
   PubMed Web of Science ®Google Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents 2013;27(3):717-28
   PubMed Web of Science ®Google Scholar
• Marchioli R, Barzi F, Bomba E, et al. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105(16):1897-903
   PubMed Web of Science ®Google Scholar
• Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1223-30
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369(9567):1090-8
   PubMed Web of Science ®Google Scholar
• Risk and Prevention Study Collaborative Group. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368(19):1800-8
   PubMed Web of Science ®Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363(21):2015-26
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367(4):309-18
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, D’Angelo A, et al. Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opin Pharmacother 2009;10(8):1239-47
   PubMed Web of Science ®Google Scholar
• Maki KC, Reeves MS, Farmer M, et al. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res 2014;34(2):126-33
   PubMedGoogle Scholar
• Berge K, Musa-Veloso K, Harwood M, et al. Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride levels. Nutr Res 2014;34(2):126-33
   PubMed Web of Science ®Google Scholar
• European Food Safety Authority. Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(7):2304-19
   Google Scholar
• Cicero AF, Derosa G, Parini A, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 2013;33(8):622-8
   PubMedGoogle Scholar
• Derosa G, Bonaventura A, Bianchi L, et al. A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. J Biol Regul Homeost Agents 2014;28(2):317-24
   PubMedGoogle Scholar
• Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009;150(12):830-9
   PubMed Web of Science ®Google Scholar